Post by
pelaboost on Feb 04, 2024 3:22pm
A layman's thoughts on Roche and Adaptive Phase 3.
I do not recall if we knew the PDAC Phase 3 was to be an Adaptive Phase 3. We have known for some time that the CPI was to be Tecentriq. Being an Adaptive Trial allows considerable flexibility (to allow for Cohort 5 of GOBLET and other changes), and the possibity of being a confirmatory trial.
We do not yet know how ONC/ONCY is going to fund this trial. I cannot see Roche stepping too far away from this, but until I have something material, I only know that Roche is supplying the CPI.
I would like to think that PanCAN is still involved in some capacity.
It does now seem a safe bet that there will be a Phase 3 pancreatic cancer trial.
Comment by
Noteable on Feb 04, 2024 11:17pm
The Phase 2 trials Reo-17 and GOBLET-1 were both adaptive clinical trials and a Phase 3 confirmation study is simply a follow-on adaptive designed study based on the previous Phase 2, as I have posted here beforehand.